RISK FACTORS FOR LONG TERM-OUTOMES IN BALLOON VALVULOPLASTY FOR AORTIC STENOSIS

ACC Oral Contributions
Georgia World Congress Center, Room B401
Monday, March 15, 2010, 11:00 a.m.-11:15 a.m.

Session Title: Catheter and Surgical Interventions in Congenital Heart Disease: From Fetus to Adult
Abstract Category: Pediatric Cardiology
Presentation Number: 0907-05

Authors: Shiraz Maskatia, Frank F. Ing, Henri Justino, Matthew A. Crystal, Charles E. Mullins, Raphael J. Mattamal, E. O’Brian Smith, Christopher J. Petit, Section Pediatric Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

Background: Balloon valvuloplasty (BV) is the primary therapy for congenital aortic valve stenosis (AS). Many reports describe short and intermediate outcomes, yet few describe predictors for long-term success.

Methods: We performed a retrospective review of patients who underwent BV for congenital AS at our institution over the past 20 years. The following endpoints were evaluated: moderate to severe aortic insufficiency by echocardiography (AI), aortic valve replacement (AVR), repeat BV, surgical aortic valvotomy, and transplant/death. Regression analysis was performed to identify risk factors for all endpoints.

Results: Between 1985 and 2009, 196 patients undergoing BV between the ages of 1 day to 30 years were followed for 4.45 (±4.85) years. Transplant or death occurred in 10 (5%) patients. Neonates were at greater risk for death or transplant (p<0.01). AVR occurred in 31 (16%) patients at a mean of 3.7 (±3.6) years. Lower baseline left ventricular shortening fraction (LVSF) (p<0.01) and younger patient age (p<0.01) were associated with AVR. AI occurred in 61 (32%) patients at a mean follow-up of 3.4 (±4.3) years. Balloon: annulus ratio >1 (p=0.02), lower LVSF (p<0.01), and a younger age at the time of BV (p<0.01) were associated with AI. Repeat intervention for recurrent stenosis (BV and/or surgical valvotomy) occurred in 25 (12.8%) patients at a mean of 3.7 (±5.4) years. Factors found to increase the rate of reintervention included: higher final valve gradient (p=0.04), lower LVSF (p=0.04), and additional left sided obstruction (p<0.01). At a follow up of 15 years post-BV, 54 (28%) patients had experienced an adverse event (repeat intervention, AVR, death or transplant). At a follow up of 10 years, 46 (23%) patients experienced an adverse event. Neonatal AS (p=0.04), lower LVSF (p<0.01) and higher final valve gradient (p<0.01) were associated with adverse events.

Conclusions: BV confers long-term benefit to most patients with congenital AS. While 25% of patients required additional procedures (repeat BV, surgical aortic valvotomy or AVR) 77% were event free at 10 years. Neonates and patients with lower LVSF experienced worse outcomes.